Acute myeloid leukemia trials in Germany

In Germany 44 Also abroad 761

44 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2/3Taking people
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Where
Brunswick, Rostock
Age
18 years to 80 years
People
312 worldwide
Run by
Moleculin Biotech, Inc.
See details and how to joinNCT06788756 · EU 2024-518359-47-00
Phase 2Taking people
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
Where
Augsburg, Erlangen, Freiburg im Breisgau, Hamburg, Jena, Mainz, Muenster
Age
Up to 64 years
People
31 worldwide
Run by
Pediatric Research International GmbH
See details and how to join2025-521390-14-00 · EU 2025-521390-14-00
Phase 2Enrolling by invitation
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Where
Brunswick, Luebeck
Age
18 years and over
People
332 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01
Phase 1/2Not yet taking people in Germany
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
Where
Berlin, Dresden, Heidelberg, Jena, Leipzig, Munich, Ulm
Age
18 years and over
People
64 worldwide
Run by
Servier
See details and how to joinNCT07719348 · EU 2025-525128-88-00
Phase 2Taking people
Phase II study of (early) combination salvage therapy with Venetoclax and intensified Decitabine in Relapsed/Refractory AML
Where
Tuebingen
Age
18 years and over
People
27
Run by
Universitaetsklinikum Tuebingen
See details and how to joinNCT06156579 · EU 2022-502665-15-00
No phaseTaking people
Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.
Where
Freiburg im Breisgau
Age
18 years and over
People
20
Run by
University of Freiburg
See details and how to joinNCT07627568
No phaseTaking people
Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
Where
Aachen, Altenburg, Augsburg, Baden-Baden, Bamberg, Bayreuth, Berlin, Bielefeld, Bochum, Bremen, Chemnitz, Coburg, Cologne, Cottbus, Donauwörth, Dresden, Duisburg, Düren, Düsseldorf, Erfurt, Erlangen, Essen, Frankfurt am Main, Frankfurt (Oder), Fulda, Gütersloh, Halle, Hamm, Heidelberg, Hildesheim, Jena, Kiel, Koblenz, Leipzig, Mannheim, Marburg, Münster, Neubrandenburg, Nuremberg, Riesa, Rostock, Rotenburg (Wümme), Schwäbisch Hall, Schwerin, Siegen, Sindelfingen, Stendal, Stuttgart, Wiesbaden, Winnenden, Wolfsburg, Würzburg, Zwickau
Age
18 years and over
People
15,000
Run by
Technische Universität Dresden
See details and how to joinNCT03188874
Phase 1Enrolling by invitation
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
Where
Berlin, Dresden, Marburg, Munich, Ulm
Age
18 years and over
People
178
Run by
AvenCell Therapeutics, Inc.
See details and how to joinNCT07474051 · EU 2025-521717-67-00
No phaseTaking people
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
Where
Aschaffenburg, Augsburg, Aurich, Bad Saarow, Berlin, Bochum, Bonn, Braunschweig, Bremen, Darmstadt, Dortmund, Düsseldorf, Essen, Esslingen am Neckar, Flensburg, Frankfurt, Freiburg im Breisgau, Fulda, Giessen, Goch, Göppingen, Göttingen, Greifswald, Halle, Hamburg, Hamm, Hanau, Hanover, Heilbronn, Herne, Homburg/Saar, Kaiserslautern, Karlsruhe, Kassel, Kiel, Krefeld, Landshut, Lebach, Lemgo, Lübeck, Lüdenscheid, Ludwigshafen, Magdeburg, Mainz, Meschede, Minden, Mühlheim, München, Mutlangen, Neuss, Offenbach, Offenburg, Oldenburg, Passau, Potsdam, Recklinghausen, Regensburg, Rostock, Saarbrücken, Saarlouis, Sande, Stuttgart, Traunstein, Trier, Tübingen, Ulm, Villingen-Schwenningen, Wernigerode, Wuppertal
Age
18 years and over
People
50,000 worldwide
Run by
University of Ulm
See details and how to joinNCT01252485
Phase 2Not yet taking people in Germany
Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation
Where
Tuebingen
Age
18 years to 75 years
People
27
Run by
University Hospital Tuebingen
See details and how to joinNCT07214064 · EU 2025-521372-62-00
Phase 1/2Taking people
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Where
Chemnitz, Halle (Saale), Leipzig
Age
18 years and over
People
78 worldwide
Run by
AB Science
See details and how to joinNCT05211570 · EU 2024-516641-39-00
Phase 1/2Not yet taking people in Germany
An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
Where
Munich, Ulm
Age
18 years and over
People
143 worldwide
Run by
Advesya SAS
See details and how to joinNCT06281847
Phase 1/2Taking people
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
Where
Aachen, Augsburg, Chemnitz, Dresden, Duesseldorf, Essen, Frankfurt Am Main, Halle (Saale), Heidelberg, Jena, Kiel, Koblenz, Leipzig, Mannheim, Marburg, Muenster, Munich, Nuremberg, Paderborn, Regensburg, Stuttgart, Wiesbaden, Winnenden
Age
18 years to 75 years
People
214
Run by
Technische Universität Dresden
See details and how to joinNCT04385290 · EU 2024-514014-13-00
Phase 1/2Taking people
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Where
Berlin, Brunswick, Leipzig
Age
18 years and over
People
240 worldwide
Run by
Aptose Biosciences Inc.
See details and how to joinNCT03850574 · EU 2023-503244-14-00
Phase 3Taking people
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Where
Berlin, Bochum, Bonn, Braunschweig, Bremen, Darmstadt, Flensburg, Freiburg im Breisgau, Greifswald, Halle, Hamburg, Hanover, Heilbronn, Karlsruhe, Mainz, Minden, München, Oldenburg, Regensburg, Stuttgart, Tübingen, Ulm
Age
18 years and over
People
227 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07075016
Phase 2Taking people
Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
Where
Aachen, Augsburg, Chemnitz, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Heidelberg, Leipzig, Munich, Münster, Wiesbaden
Age
18 years and over
People
60
Run by
Technische Universität Dresden
See details and how to joinNCT06696183 · EU 2023-507878-41-00
Phase 1Not yet taking people in Germany
Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML
Where
Dresden, Heidelberg
Age
18 years and over
People
12
Run by
German Cancer Research Center
See details and how to joinNCT05662904
Phase 1/2Not yet taking people in Germany
An adaptive open-label multicentre phase 1/2 trial, to determine the recommended phase 2 dose of CCTx-001, and to assess safety, tolerability, and clinical activity in patients with relapsed/refractory acute myeloid leukaemia (RESOLVE AML 001)
Where
Munich, Ulm
Age
18 years and over
People
61 worldwide
Run by
CanCell Therapeutics
See details and how to join2023-506865-71-00 · EU 2023-506865-71-00
Phase 2Taking people
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Where
Essen
Age
Up to 18 years
People
89 worldwide
Run by
Associazione Italiana Ematologia Oncologia Pediatrica
See details and how to joinNCT04793919 · EU 2024-518669-83-00